PMID- 28982571
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20201216
IS  - 1876-7591 (Electronic)
IS  - 1936-878X (Print)
IS  - 1876-7591 (Linking)
VI  - 10
IP  - 10 Pt A
DP  - 2017 Oct
TI  - Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis 
      of Nonischemic Cardiomyopathy.
PG  - 1180-1193
LID - S1936-878X(17)30776-3 [pii]
LID - 10.1016/j.jcmg.2017.08.005 [doi]
AB  - Cardiac magnetic resonance (CMR) is a valuable tool for the evaluation of 
      patients with, or at risk for, heart failure and has a growing impact on 
      diagnosis, clinical management, and decision making. Through its ability to 
      characterize the myocardium by using multiple different imaging parameters, it 
      provides insight into the etiology of the underlying heart failure and its 
      prognosis. CMR is widely accepted as the reference standard for quantifying 
      chamber size and ejection fraction. Additionally, tissue characterization 
      techniques such as late gadolinium enhancement (LGE) and other quantitative 
      parameters such as T(1) mapping, both native and with measurement of 
      extracellular volume fraction; T(2) mapping; and T(2)* mapping have been 
      validated against histological findings in a wide range of clinical scenarios. In 
      particular, the pattern of LGE in the myocardium can help determine the 
      underlying etiology of the heart failure. The presence and extent of LGE 
      determine prognosis in many of the nonischemic cardiomyopathies. The use of CMR 
      should increase as its utility in characterization and assessment of prognosis in 
      cardiomyopathies is increasingly recognized.
CI  - Copyright (c) 2017 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Patel, Amit R
AU  - Patel AR
AD  - Department of Medicine and Radiology, University of Chicago, Chicago, Illinois.
FAU - Kramer, Christopher M
AU  - Kramer CM
AD  - Departments of Medicine and Radiology and the Cardiovascular Imaging Center, 
      University of Virginia Health System, Charlottesville, Virginia. Electronic 
      address: ckramer@virginia.edu.
LA  - eng
GR  - U01 HL117006/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
RN  - 0 (Contrast Media)
SB  - IM
MH  - Amyloidosis/diagnostic imaging
MH  - Cardiomyopathies/*diagnostic imaging/genetics/therapy
MH  - Cardiomyopathy, Dilated/diagnostic imaging
MH  - Cardiomyopathy, Hypertrophic/diagnostic imaging
MH  - Contrast Media/administration & dosage
MH  - Genetic Predisposition to Disease
MH  - Hemosiderosis/diagnostic imaging
MH  - Humans
MH  - Image Interpretation, Computer-Assisted
MH  - *Magnetic Resonance Imaging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
MH  - Sarcoidosis/diagnostic imaging
MH  - Severity of Illness Index
PMC - PMC5708889
MID - NIHMS900410
OTO - NOTNLM
OT  - amyloidosis
OT  - cardiomyopathy
OT  - cardiovascular magnetic resonance
OT  - heart failure
OT  - hypertrophic cardiomyopathy
OT  - sarcoidosis
EDAT- 2017/10/07 06:00
MHDA- 2018/06/12 06:00
PMCR- 2018/10/01
CRDT- 2017/10/07 06:00
PHST- 2017/04/27 00:00 [received]
PHST- 2017/08/04 00:00 [revised]
PHST- 2017/08/10 00:00 [accepted]
PHST- 2017/10/07 06:00 [entrez]
PHST- 2017/10/07 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2018/10/01 00:00 [pmc-release]
AID - S1936-878X(17)30776-3 [pii]
AID - 10.1016/j.jcmg.2017.08.005 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt A):1180-1193. doi: 
      10.1016/j.jcmg.2017.08.005.